结核中空纤维系统模型的可重复性及药物与联合治疗开发最佳实践的性能规范
BACKGROUND: The hollow-fibre system model of tuberculosis (HFS-TB) has been endorsed by regulators; however, application of HFS-TB requires a thorough understanding of intra- and inter-team variability, statistical power and quality controls.…
要点
- HFS-TB达标准确率:接种物>98%,药代动力学暴露>88%,偏倚95%CI均跨零。
- 团队效应占各时间点log10 cfu/mL变异<1%,杀灭斜率变异系数5.10%(95%CI 3.36%-6.85%)。
- 所有REMoxTB组杀灭斜率几乎相同,高剂量方案快33%;至少3个重复单位可>99%效能识别>20%斜率差异。
核心结论
- HFS-TB是选择联合方案的高度可操控工具,团队间和重复间变异很小。
研究设计与样本
- 三个团队评估与REMoxTB研究匹配的方案及两个高剂量利福平/吡嗪酰胺/莫西沙星方案,每日给药最长28或56天,针对对数生长期、胞内生长或酸性条件下半休眠生长的结核分枝杆菌(Mtb)。
- 目标接种量和药代动力学参数预先设定,采用各采样点变异系数百分比(%CV)和双向方差分析(ANOVA)计算达标准确度与偏倚。
主要发现
- 达标准确率:接种物>98%,药代动力学暴露>88%;偏倚的95%CI在所有情况下均跨零。
- ANOVA显示团队效应占各时间点log10 cfu/mL变异的<1%。
- 各方案和不同Mtb代谢群的杀灭斜率%CV为5.10%(95%CI:3.36%-6.85%)。
- 所有REMoxTB组杀灭斜率几乎相同,而高剂量方案快33%;样本量分析显示至少需要三个重复HFS-TB单位才能以>99%效能识别>20%的斜率差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The hollow-fibre system model of tuberculosis (HFS-TB) has been endorsed by regulators; however, application of HFS-TB requires a thorough understanding of intra- and inter-team variability, statistical power and quality controls. METHODS: Three teams evaluated regimens matching those in the Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) study, plus two high-dose rifampicin/pyrazinamide/moxifloxacin regimens, administered daily for up to 28 or 56 days against Mycobacterium tuberculosis (Mtb) under log-phase growth, intracellular growth or semidormant growth under acidic conditions. Target inoculum and pharmacokinetic parameters were pre-specified, and the accuracy and bias at achieving these calculated using percent coefficient of variation (%CV) at each sampling point and two-way analysis of variance (ANOVA). RESULTS: A total of 10 530 individual drug concentrations, and 1026 individual cfu counts were measured. The accuracy in achieving intended inoculum was >98%, and >88% for pharmacokinetic exposures. The 95% CI for the bias crossed zero in all cases. ANOVA revealed that the team effect accounted for <1% of variation in log10 cfu/mL at each timepoint. The %CV in kill slopes for each regimen and different Mtb metabolic populations was 5.10% (95% CI: 3.36%-6.85%). All REMoxTB arms exhibited nearly identical kill slopes whereas high dose regimens were 33% faster. Sample size analysis revealed that at least three replicate HFS-TB units are needed to identify >20% difference in slope, with a power of >99%. CONCLUSIONS: HFS-TB is a highly tractable tool for choosing combination regimens with little variability between teams, and between replicates.
引用
- Gumbo T, Srivastava S, Deshpande D, et al. Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development. J Antimicrob Chemother. 2023. PMID: 36794692. doi:10.1093/jac/dkad029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。